Correlation Between Diabetic Peripheral Neuropathy and Sarcopenia in Patients with Type 2 Diabetes Mellitus and Diabetic Foot Disease: A Cross-Sectional Study
Open Access
- 1 February 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 13, 377-386
- https://doi.org/10.2147/dmso.s237362
Abstract
Purpose: The present study was designed to determine the relationships between sarcopenia and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM) and diabetic foot disease (DFD) respectively. Patients and Methods: A total of 1104 patients with T2DM and 257 patients with DFD were included in the study, which was designed as a cross-sectional study. Body composition was assessed using dual-energy X-ray-absorptiometry (DXA). The diagnosis of sarcopenia was based on the Baumgartner criteria. DPN was assessed by Neuropathy symptom score (NSS) and Neuropathy disability score (NDS), and the severity of neuropathy was divided into non-neuropathy symptom (NS), Mild NS, Moderate NS and Severe NS according to NSS. Logistic regression analyses were carried out to determine the relations of sarcopenia and DPN in patients with T2DM and NSS in patients with DFD, respectively. Results: The prevalence of DPN was 80.0% in T2DM patients with sarcopenia and 70.3% in non-sarcopenia patients (P=0.007). Logistic regression analyses showed DPN was one of the independent risk factors for sarcopenia in T2DM patients (OR 1.564 [95% CI: 1.004, 2.435], P=0.048). The prevalence of DPN had no statistical significance in DFD patients with or without sarcopenia. However, the NSS of DFD patients with sarcopenia was higher than that of non-sarcopenia patients. In the multivariate logistic regression analysis, NSS was determined to be associated with sarcopenia in DFD patients (OR 1.387[95% CI: 1.074, 1.789], P=0.012). The appendicular lean mass (ALM) of DFD patients without NS was higher than patients with mild, moderate and severe NS (20.71± 2.73 vs 16.57± 3.62 vs 17.99± 3.54 vs 17.23± 3.29 Kg, P=0.028). Conclusion: DPN is an independent risk factor for sarcopenia in patients with T2DM and NSS is also independently correlated with sarcopenia in patients with DFD, with the latter being more obvious with the aggravation of neurological symptoms in DFD patients.Keywords
This publication has 40 references indexed in Scilit:
- Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophyBiological Chemistry, 2013
- Standards of Medical Care in Diabetes—2012Diabetes Care, 2011
- Developing and Validating a Risk Score for Lower-Extremity Amputation in Patients Hospitalized for a Diabetic Foot InfectionDiabetes Care, 2011
- Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on SarcopeniaJournal of the American Medical Directors Association, 2011
- The global burden of diabetes and its complications: an emerging pandemicEuropean Journal of Preventive Cardiology, 2010
- Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 DiabetesDiabetes Care, 2010
- Absence of insulin signalling in skeletal muscle is associated with reduced muscle mass and function: evidence for decreased protein synthesis and not increased degradationAGE, 2010
- Excessive Adipose Tissue Infiltration in Skeletal Muscle in Individuals With Obesity, Diabetes Mellitus, and Peripheral Neuropathy: Association With Performance and FunctionPTJ: Physical Therapy & Rehabilitation Journal, 2008
- Diabetes-Related Complications, Glycemic Control, and Falls in Older AdultsDiabetes Care, 2008
- Does diabetes mellitus target motor neurons?Neurobiology of Disease, 2007